In the big picture, you are absolutely right. TLD is the big indicator. GNP certification is not as important, though it does give NWBO a chance to increase it's short term revenue stream. That is helpful for paying off debt and running the company, but the valuation is not dependent upon that revenue. Valuation will be based on potential future revenue. This company is valued as a 'tech' in terms of future revenue and not as a biopharma on current revenue, even with a healthy revenue stream which is what GMP cert will generate.